UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tandem-STRAIGHT: A temporally stable power spectral representation for periodic signals and applications to interference-free spectrum, F0, and aperiodicity estimation

2008 IEEE International Conference on Acoustics, Speech and Signal Processing, 2008, p.3933-3936

2008

Volltextzugriff (PDF)

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

ESMO open, 2022-08, Vol.7 (4), p.100527, Article 100527

2022

Volltextzugriff (PDF)

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

ESMO open, 2021-06, Vol.6 (3), p.100115-100115, Article 100115

2021

Volltextzugriff (PDF)

Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

Annals of oncology, 2019-04, Vol.30, p.ii66-ii66

2019

Volltextzugriff (PDF)

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Annals of oncology, 2019-10, Vol.30, p.v915

2019

Volltextzugriff (PDF)

Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data

Annals of oncology, 2018-11, Vol.29, p.ix152-ix152

2018

Volltextzugriff (PDF)

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study

ESMO open, 2024-08, Vol.9 (8), p.103642, Article 103642

2024

Volltextzugriff (PDF)

Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer

Japanese journal of clinical oncology, 2014-09, Vol.44 (9), p.846-851

2014

Volltextzugriff (PDF)

Impact of the number of citizens officially certified for government-organized civilian cardiopulmonary resuscitation courses on the prognosis for patients with out-of-hospital cardiac arrest in Japan

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

533P Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs

Annals of oncology, 2023-11, Vol.34, p.S1678

2023

Volltextzugriff (PDF)

An interference-free representation of instantaneous frequency of periodic signals and its application to F0 extraction

2011 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP), 2011, p.5420-5423

2011

Volltextzugriff (PDF)

396P Comparison of the incidence of skeletal related events (SREs) between non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)

Annals of oncology, 2015-12, Vol.26, p.ix111-ix111

2015

Volltextzugriff (PDF)

EP11.03-32 Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy?

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S633-S634

2023

Volltextzugriff (PDF)

Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer

Annals of oncology, 2019-11, Vol.30, p.ix176

2019

Volltextzugriff (PDF)

46P Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S68

2023

Volltextzugriff (PDF)

321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

Annals of oncology, 2022-11, Vol.33, p.S1565-S1565

2022

Volltextzugriff (PDF)

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S360

2023

Volltextzugriff (PDF)

977P Phase II study of brigatinib in patients with tyrosine kinase inhibitor (TKI)-naïve ROS1-rearranged advanced non-small cell lung cancer (NSCLC): Barossa cohort 1

Annals of oncology, 2022-09, Vol.33, p.S996-S997

2022

Volltextzugriff (PDF)

Temporally variable multi-aspect auditory morphing enabling extrapolation without objective and perceptual breakdown

2009 IEEE International Conference on Acoustics, Speech and Signal Processing, 2009, p.3905-3908

2009

Volltextzugriff (PDF)

P2.10-02 Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S352

2023

Volltextzugriff (PDF)

25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping

Annals of oncology, 2022-04, Vol.33, p.S41-S42

2022

Volltextzugriff (PDF)

Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION

International journal of radiation oncology, biology, physics, 2022-02, Vol.112 (2), p.e14-e15

2022

Volltextzugriff (PDF)

P47.14 Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1102-S1103

2021

Volltextzugriff (PDF)

P89.06 Prospective Concordance Study of a Multi-Gene PCR Assay and NGS for the Detection of Targetable Gene Alterations in Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S690-S690

2021

Volltextzugriff (PDF)

OA02.04 Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion-Positive NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S851-S851

2021

Volltextzugriff (PDF)

1 – 25 von 302

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(240)
Mit Volltextzugriff
(234)

Publikationsform

Artikel
(290)
Tagungsberichte
(12)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Humans
(119)
Life Sciences & Biomedicine
(93)
Male
(90)
Female
(70)
Middle Aged
(69)
Adult
(67)
Biological And Medical Sciences
(52)
Aged
(42)
Medical Sciences
(41)
Animals
(25)
Cardiovascular System & Cardiology
(23)
Physical Sciences
(23)
Cardiac & Cardiovascular Systems
(15)
Cardiology. Vascular System
(15)
Gastroenterology & Hepatology
(15)
Physics
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Chemistry
(13)
Exact Sciences And Technology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tandem-STRAIGHT: A temporally stable power spectral representation for periodic signals and applications to interference-free spectrum, F0, and aperiodicity estimation

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study

Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer

Impact of the number of citizens officially certified for government-organized civilian cardiopulmonary resuscitation courses on the prognosis for patients with out-of-hospital cardiac arrest in Japan

533P Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs

An interference-free representation of instantaneous frequency of periodic signals and its application to F0 extraction

396P Comparison of the incidence of skeletal related events (SREs) between non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)

EP11.03-32 Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy?

Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer

46P Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study

321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

977P Phase II study of brigatinib in patients with tyrosine kinase inhibitor (TKI)-naïve ROS1-rearranged advanced non-small cell lung cancer (NSCLC): Barossa cohort 1

Temporally variable multi-aspect auditory morphing enabling extrapolation without objective and perceptual breakdown

P2.10-02 Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid)

25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping

Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION

P47.14 Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC

P89.06 Prospective Concordance Study of a Multi-Gene PCR Assay and NGS for the Detection of Targetable Gene Alterations in Lung Cancer

OA02.04 Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion-Positive NSCLC

Suchergebnisse filtern